Page last updated: 2024-12-08
salicylic acid glucoside
Description
salicylic acid glucoside: structure given in first source; induces pathogenesis-related protein expression in tobacco; involved in systemic acquired resistance [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
2-(D-glucosyloxy)benzoic acid : A monosaccharide derivative that is salicylic acid in which the phenolic hydrogen is replaced by a D-glucosyl residue. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 151505 |
| CHEBI ID | 87766 |
| SCHEMBL ID | 4281885 |
| MeSH ID | M0225096 |
Synonyms (20)
| Synonym |
|---|
| salicylic acid glucoside |
| 3D77C27E-4425-4724-A323-C2DDF33E5E4C |
| salicylic acid-glucopyranoside |
| 2-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzoic acid |
| 10366-91-3 |
| salicylic acid beta-glucoside |
| SCHEMBL4281885 |
| 2-(d-glucosyloxy)benzoic acid |
| o-glucosylsalicylic acid |
| CHEBI:87766 |
| salicylic acid glucopyranoside |
| 2-{[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}benzoic acid |
| 2-(d-glucopyranosyloxy)benzoic acid |
| J-001018 |
| 2-(beta-d-glucopyranosyloxy)-benzoic acid |
| Q27159910 |
| glucosylsalicylic acid |
| 2-(hexopyranosyloxy)benzoic acid |
| DTXSID50908542 |
| salicylic acid 2-o- beta -d-glucoside |
Drug Classes (3)
| Class | Description |
|---|
| D-glucoside | Any glucoside in which the glycoside group is derived from D-glucose. |
| monosaccharide derivative | A carbohydrate derivative that is formally obtained from a monosaccharide. |
| benzoic acids | Any aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (15)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 24.88
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 24.88 (24.57) | | Research Supply Index | 2.89 (2.92) | | Research Growth Index | 4.69 (4.65) | | Search Engine Demand Index | 23.70 (26.88) | | Search Engine Supply Index | 2.33 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |